Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
Rheumatology, University of Debrecen, Debrecen, Hungary.
RMD Open. 2021 Jan;7(1). doi: 10.1136/rmdopen-2020-001512.
To summarise, by a systematic literature review (SLR), the evidence regarding pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis (D2T RA), informing the EULAR recommendations for the management of D2T RA.
PubMed, Embase and Cochrane databases were searched up to December 2019. Relevant papers were selected and appraised.
Two hundred seven (207) papers studied therapeutic strategies. Limited evidence was found on effective and safe disease-modifying antirheumatic drugs (DMARDs) in patients with comorbidities and other contraindications that limit DMARD options (patients with obesity, hepatitis B and C, risk of venous thromboembolisms, pregnancy and lactation). In patients who previously failed biological (b-)DMARDs, all currently used b/targeted synthetic (ts-)DMARDs were found to be more effective than placebo. In patients who previously failed a tumour necrosis factor inhibitor (TNFi), there was a tendency of non-TNFi bDMARDs to be more effective than TNFis. Generally, effectiveness decreased in patients who previously failed a higher number of bDMARDs. Additionally, exercise, psychological, educational and self-management interventions were found to improve non-inflammatory complaints (mainly functional disability, pain, fatigue), education to improve goal setting, and self-management programmes, educational and psychological interventions to improve self-management.The identified evidence had several limitations: (1) no studies were found in patients with D2T RA specifically, (2) heterogeneous outcome criteria were used and (3) most studies had a moderate or high risk of bias.
This SLR underscores the scarcity of high-quality evidence on the pharmacological and non-pharmacological treatment of patients with D2T RA. Effectiveness of b/tsDMARDs decreased in RA patients who had failed a higher number of bDMARDs and a subsequent b/tsDMARD of a previously not targeted mechanism of action was somewhat more effective. Additionally, a beneficial effect of non-pharmacological interventions was found for improvement of non-inflammatory complaints, goal setting and self-management.
通过系统文献综述(SLR)总结治疗难治性类风湿关节炎(D2T RA)的药物和非药物治疗策略的证据,为 D2T RA 的管理提供 EULAR 建议。
检索了 PubMed、Embase 和 Cochrane 数据库,截至 2019 年 12 月。选择并评估了相关文献。
207 篇论文研究了治疗策略。在患有合并症和其他限制 DMARD 选择的禁忌症(如肥胖、乙型和丙型肝炎、静脉血栓栓塞风险、妊娠和哺乳期)的患者中,发现有效且安全的疾病修饰抗风湿药物(DMARDs)的证据有限。在先前失败生物(b)-DMARDs 的患者中,所有目前使用的 b/靶向合成(ts)-DMARDs 均被发现比安慰剂更有效。在先前失败肿瘤坏死因子抑制剂(TNFi)的患者中,非 TNFi bDMARDs 比 TNFis 更有效。一般来说,在先前失败更多 bDMARDs 的患者中,有效性降低。此外,运动、心理、教育和自我管理干预措施被发现可改善非炎症性投诉(主要是功能障碍、疼痛、疲劳),教育可改善目标设定,自我管理计划、教育和心理干预可改善自我管理。所确定的证据存在一些局限性:(1)未发现专门针对 D2T RA 患者的研究;(2)使用了不同的结果标准;(3)大多数研究存在中度或高度偏倚风险。
这项 SLR 强调了缺乏高质量证据来治疗 D2T RA 患者的药物和非药物治疗。在先前失败更多 bDMARDs 的 RA 患者中,b/tsDMARDs 的有效性降低,先前未靶向作用机制的 b/tsDMARD 稍有效。此外,还发现非药物干预对改善非炎症性投诉、目标设定和自我管理具有有益作用。